C.L. King analyst Kristen Stewart maintains $Boston Scientific (BSX.US)$ with a buy rating, and adjusts the target price from $64 to $90.
According to TipRanks data, the analyst has a success rate of 60.6% and a total average return of 3.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific has reported a quarter that exceeded expectations on all fronts, despite high expectations. Nonetheless, the company's shares are experiencing pressure due to the announced pause in the AVANT GUARD clinical trial, which is investigating Farapulse in a new patient segment. It is noted that this particular segment is not currently receiving treatment, there are observations under assessment, and the expectation is for enrollment to recommence shortly.
Boston Scientific's Q3 outcomes were deemed impressive, with management raising its 2024 guidance to reflect a departure from the year at +15% organic sales growth. Despite a temporary halt in an EP trial, AVANTGUARD, which led to a decrease in stock value, assessments with key opinion leaders suggest that the reaction may have been exaggerated.
Following Boston Scientific's Q3 report, it was noted that the AVANT Guard trial setback is not associated with a mortality event nor initiated by the FDA, and that momentum for Farapulse globally is expected to be sustainable over the medium term. The recent decline in Boston Scientific's share price is seen as a 'compelling' opportunity for entry.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
CL King分析師Kristen Stewart維持$波士頓科學 (BSX.US)$買入評級，並將目標價從64美元上調至90美元。
根據TipRanks數據顯示，該分析師近一年總勝率為60.6%，總平均回報率為3.5%。
此外，綜合報道，$波士頓科學 (BSX.US)$近期主要分析師觀點如下：
波士頓科學報告的一個季度在所有方面都超出了預期，儘管市場對其期望較高。然而，該公司股價正面臨壓力，因爲宣佈了AVANt GUARD臨床試驗暫停，該試驗正在研究Farapulse在一種新的患者群體中的應用。需要注意的是，該特定群體目前尚未接受治療，正在進行評估觀察，預計很快將恢復招募。
波士頓科學的第三季度業績被認爲令人印象深刻，管理層將其2024年指引上調，以反映年度有機銷售增長+15%的預期。儘管在一個EP試驗AVANTGUARD中暫停，導致股價下跌，但與合鍵意見領袖的評估表明，市場可能過於誇大了這種反應。
根據波士頓科學的第三季度報告，AVANt Guard試驗的挫折與死亡事件無關，也不是FDA發起的，全球Farapulse的動能有望在中期內持續發展。波士頓科學股價最近的下跌被視爲一個「引人注目」的入場機會。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
